Skip to content

Effect of Intraurethral Guardix-SOL Application on Postoperative Voiding Function After Transurethral Resection of Bladder Tumor: A Prospective Randomized Controlled Study

Effect of Intraurethral Guardix-SOL Application on Postoperative Voiding Function After Transurethral Resection of Bladder Tumor: A Prospective Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0012256
Enrollment
100
Registered
2026-07-08
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : A single-center, prospective, randomized, assessor-blinded, parallel-group comparative study with 1:1 block randomization (using variable block sizes). Subjects will be randomized seq

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • Patients scheduled to undergo transurethral resection of bladder tumor (TUR-BT) • Adult patients aged 19 years or older • Patients who have received a sufficient explanation regarding the purpose and procedures of the study and have provided written informed consent

Exclusion criteria

Exclusion criteria: • Patients with a prior diagnosis of urethral stricture • Patients with a history of undergoing transurethral resection of bladder tumor (TUR-BT). (However, the initial resection (Initial transurethral resection of bladder tumor) performed for confirmation of diagnosis and staging is excluded from this history.) • Patients scheduled for radical cystectomy • Patients with an active urinary tract infection (UTI) • Patients with neurogenic bladder • Patients who have undergone major lower urinary tract surgery within the last 3 months • Patients with an anticipated clinical condition that may affect the interpretation of study results, such as severe voiding dysfunction • Patients whose participation in the study is deemed clinically inappropriate

Design outcomes

Primary

MeasureTime frame
Confirmation of changes in the International Prostate Symptom Score (IPSS) voiding subscore

Secondary

MeasureTime frame
Confirmation of postoperative pain;duration of gross hematuria

Countries

Korea, Republic of

Contacts

Public ContactHong sunghoo

The Catholic University of Korea, Seoul St. Mary's Hospital

toomey@catholic.ac.kr+82-2-2258-6628

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Jul 23, 2026